Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
IBER.WS
IBER.WS was delisted on the 15th of February, 2023.
20 hedge funds and large institutions have $3.27M invested in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$167K |
| 2 |
LA
Linden Advisors
New York
|
+$137K |
| 3 |
SC
Sculptor Capital
New York
|
+$129K |
| 4 |
SCC
Spring Creek Capital
Wichita,
Kansas
|
+$121K |
| 5 |
VI
Vestcor Inc
Fredericton,
New Brunswick, Canada
|
+$121K |
Top Sellers
IBER.WS Hedge Fund Activity: Q2 2021 in Review
20 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) for Q2 2021, worth a combined $3.27M.
Buyers outnumbered sellers: 20 funds opened new IBER.WS positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $167K.
- 20 institutional investors held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $3.27M of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share stock for Q2 2021.
- 20 funds opened new Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share positions in Q2 2021 and 0 closed out, a net change of +20 holders.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share buyer in Q2 2021 was Citadel Advisors, an estimated $167K added.
Based on aggregated 13F filings for Q2 2021.